GMAB Relative Valuation
GMAB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GMAB is overvalued; if below, it's undervalued.
Historical Valuation
Genmab A/S (GMAB) is now in the Fair zone, suggesting that its current forward PE ratio of 22.37 is considered Fairly compared with the five-year average of 39.27. The fair price of Genmab A/S (GMAB) is between 17.74 to 79.84 according to relative valuation methord.
Relative Value
Fair Zone
17.74-79.84
Current Price：31.68
Fair
22.61
PE
1Y
3Y
5Y
Trailing
Forward
8.26
EV/EBITDA
Genmab A/S. (GMAB) has a current EV/EBITDA of 8.26. The 5-year average EV/EBITDA is 28.37. The thresholds are as follows: Strongly Undervalued below -24.45, Undervalued between -24.45 and 1.96, Fairly Valued between 54.78 and 1.96, Overvalued between 54.78 and 81.18, and Strongly Overvalued above 81.18. The current Forward EV/EBITDA of 8.26 falls within the Historic Trend Line -Fairly Valued range.
9.35
EV/EBIT
Genmab A/S. (GMAB) has a current EV/EBIT of 9.35. The 5-year average EV/EBIT is 27.25. The thresholds are as follows: Strongly Undervalued below -9.30, Undervalued between -9.30 and 8.98, Fairly Valued between 45.52 and 8.98, Overvalued between 45.52 and 63.80, and Strongly Overvalued above 63.80. The current Forward EV/EBIT of 9.35 falls within the Historic Trend Line -Fairly Valued range.
4.65
PS
Genmab A/S. (GMAB) has a current PS of 4.65. The 5-year average PS is 10.24. The thresholds are as follows: Strongly Undervalued below -1.21, Undervalued between -1.21 and 4.52, Fairly Valued between 15.97 and 4.52, Overvalued between 15.97 and 21.69, and Strongly Overvalued above 21.69. The current Forward PS of 4.65 falls within the Historic Trend Line -Fairly Valued range.
17.98
P/OCF
Genmab A/S. (GMAB) has a current P/OCF of 17.98. The 5-year average P/OCF is 32.83. The thresholds are as follows: Strongly Undervalued below -2.71, Undervalued between -2.71 and 15.06, Fairly Valued between 50.60 and 15.06, Overvalued between 50.60 and 68.37, and Strongly Overvalued above 68.37. The current Forward P/OCF of 17.98 falls within the Historic Trend Line -Fairly Valued range.
15.55
P/FCF
Genmab A/S. (GMAB) has a current P/FCF of 15.55. The 5-year average P/FCF is 37.70. The thresholds are as follows: Strongly Undervalued below 2.08, Undervalued between 2.08 and 19.89, Fairly Valued between 55.51 and 19.89, Overvalued between 55.51 and 73.33, and Strongly Overvalued above 73.33. The current Forward P/FCF of 15.55 falls within the Undervalued range.
Genmab A/S (GMAB) has a current Price-to-Book (P/B) ratio of 0.34. Compared to its 3-year average P/B ratio of 3.78 , the current P/B ratio is approximately -91.03% higher. Relative to its 5-year average P/B ratio of 5.33, the current P/B ratio is about -93.64% higher. Genmab A/S (GMAB) has a Forward Free Cash Flow (FCF) yield of approximately 6.79%. Compared to its 3-year average FCF yield of 5.35%, the current FCF yield is approximately 26.95% lower. Relative to its 5-year average FCF yield of 4.05% , the current FCF yield is about 67.51% lower.
0.34
P/B
Median3y
3.78
Median5y
5.33
6.84
FCF Yield
Median3y
5.35
Median5y
4.05
Competitors Valuation Multiple
The average P/S ratio for GMAB's competitors is 3.46, providing a benchmark for relative valuation. Genmab A/S Corp (GMAB) exhibits a P/S ratio of 4.65, which is 34.20% above the industry average. Given its robust revenue growth of 25.25%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of GMAB increased by 53.43% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 22.79 to 39.24.
The secondary factor is the Revenue Growth, contributed 25.25%to the performance.
Overall, the performance of GMAB in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Genmab A/S (GMAB) currently overvalued or undervalued?
What is Genmab A/S (GMAB) fair value?
How does GMAB's valuation metrics compare to the industry average?
What is the current P/B ratio for Genmab A/S (GMAB) as of Dec 05 2025?
What is the current FCF Yield for Genmab A/S (GMAB) as of Dec 05 2025?
What is the current Forward P/E ratio for Genmab A/S (GMAB) as of Dec 05 2025?